Advertisement

Psychopharmacology

, Volume 98, Issue 2, pp 157–162 | Cite as

Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat

  • David J. Fontana
  • Timothy J. Carbary
  • Randall L. Commissaris
Original Investigations

Abstract

The present studies were undertaken to evaluate further the utility of the Conditioned Suppression of Drinking (CSD) conflict pardigm as an animal model for the study of panic disorder and anti-panic agents. In daily 10-min sessions, water-deprived rats were trained to drink from a tube which was occasionally electrified (0.5 mA). Electrification was signalled by a tone. Desipramine (DMI), amitriptyline (AMI), or phenelzine (PHEN) was administered both in acute (10-min pre-treatment) and chronic (twice daily for up to 9 weeks) regimens. Acute administration of DMI, AMI or PHEN over a wide range of doses resulted in no change or a decrease in the number of shocks accepted and a decrease in water intake at higher doses. In contrast, chronic administration of each agent resulted in a gradual (2–4 week latency) increase in the number of shocks received in CSD sessions over the course of several weeks of testing. This time-dependent increase in punished responding in the CSD observed during chronic anti-panic drug treatment parallels the time-dependent reduction in the severity and frequency of panic attacks in panic disorder patients receiving chronic antidepressants. Thus, the CSD paradigm might serve as an animal model for the study of panic disorder and potential anti-panic agents.

Key words

Panic disorder Generalized anxiety Conditioned Suppression of Drinking (CSD) Desipramine Amitriptyline Phenelzine Conflict behavior Anti-panic drugs Antidepressants 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, ed 3. American Psychiatric Association, Washington, DCGoogle Scholar
  2. Banerjee SD, Kung LS, Riggi SJ, Chanda SK (1977) Development of beta-receptor subsensitivity and antidepressants. Nature 268:455–457Google Scholar
  3. Beaudry P, Fontaine R, Chouinard G, Annable L (1986) Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry 74 (2):83–85Google Scholar
  4. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ (1988) The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 95:298–302Google Scholar
  5. Cassella JV, Davis M (1985) Fear-enhanced acoustic startle is not attentuated by acute or chronic imipramine treatment in rats. Psychopharmacology 87 (3):278–282Google Scholar
  6. Charney DS, Menkes DB, Henninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 38:1160–1180Google Scholar
  7. Chouinard G, Annable L, Fontaine R, Solyom L (1982) Alprazolam in the treatment of genralized anxiety and panic disorder: a double-blind placebo-controlled study. Psychopharmacology 77:229–282Google Scholar
  8. Commissaris RL, Harrington GH, Ortiz AM, Altman HJ (1986) Maudsley reactive and non-reactive rat strains: differential performance in a conflict task. Physiol Behav 38:291–294Google Scholar
  9. Davis M, Menkes DF (1982) Tricyclic antidepressants vary in decreasing alpha-2-adrenoceptor sensitivity with chronic treatment: assessment with clonidine inhibition of acoustic startle. Br J Pharmacol 77:217–222Google Scholar
  10. Ellis DM, Fontana DJ, Commissaris RL (1988) Acute and chronic mianserin treatment: failure to produce an “anti-panic” effect on conflict behavior in the rat. Can Fed Biol Soc 31:54Google Scholar
  11. File SE (1981) How good is social interaction as a test of anxiety? In: Simon P, Soubrie P, Wildlocher D (eds) Animal models of Anxiety, depression and psychosis. Karger, Basel, pp 151–166Google Scholar
  12. File SE, Johnston AL (1987) Chronic treatment with imipramine does not reverse the effects of 3 anxiogenic compounds in a test of anxiety in the rat. Neuropsychobiology 17:187–192Google Scholar
  13. File SE, Pellos S, Chapin P (1985) Can animal tests of anxiety detect anti-panic compounds? Neurosci Abstr 11:273Google Scholar
  14. Fontana DJ, Commissaris RL (1988) Effects of acute and chronic imipramine administration on conflict behavior in the rat: a potential “animal model” for the study of panic disorder? Psychopharmacology 95:147–150Google Scholar
  15. Garakani H, Zitrin CH, Klein DF (1984) Treatment of panic disorder with imipramine alone. Am J Psychiatry 141:446–448Google Scholar
  16. Geller I, Seifter J (1960) The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally-induced conflict in the rat. Psychopharmacology 1:482–492Google Scholar
  17. Geller I, Kulak JT, Seifter J (1962) Effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacology 3:374–385Google Scholar
  18. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer M, Davies SO, Klein DF (1987) An open trial of Fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7 (5):329–332Google Scholar
  19. Johnston AL, File SE (1988) The profiles of the anti-panic compounds, triazolobenzodiazepines and and phenelzine in two animal tests of anxiety. Psychiatry Res 24 (in press)Google Scholar
  20. Kelly D, Giurguis W, Frommer E, Mitchel-Heggs W, Sargant W (1970) Treatment of phobic states with antidepressants. Br J Psychiatry 16:387–398Google Scholar
  21. Kilts CD, Commissaris RL, Rech RH (1981) Comparison of anticonflict drug effects in three experimental models of anxiety. Psychopharmacology 74:290–296Google Scholar
  22. Klein DF, Fink M (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatry 119:432–438Google Scholar
  23. Klein DF (1964) Delineation on two drug-responsive anxiety syndromes. Psychopharmacology 5:397–408Google Scholar
  24. Klein DF (1967) Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 16:118–126Google Scholar
  25. Lydiard RB, Ballenger JC (1987) Antidepressants in panic disorder and agoraphobia. J Affective Disord 13 (2):153–168Google Scholar
  26. Mavissakalian M, Michelson L, Dealy RS (1983) Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 143:348–355Google Scholar
  27. McCloskey TC, Paul BK, Commissaris RL (1987) Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital. Pharmacol Biochem Behav 27:171–175Google Scholar
  28. McNair DM, Kahn RK (1981) Imipramine compared with a benzodiazepine for agrophobia. In: Klein DF, Rabkin G (eds) pp 69–80: Anxiety: new research and changing concepts. Raven Press, New YorkGoogle Scholar
  29. Muskin PR, Fyer AJ (1981) Treatment of panic disorder. J Clin Psychopharmacol 1:81–90Google Scholar
  30. Noyes R, Anderson D, Clancy J (1984) Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 41:287–292Google Scholar
  31. Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 210:88–90Google Scholar
  32. Pollack MH, Tesar GE, Rosenbaum JF, Spier SA (1986) Clonazepam in the treatment of panic disorder with agoraphobia: a one-year follow-up. J Clin Psychopharmacol 6:303–304Google Scholar
  33. Sheehan DV, Ballanger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypocondriacal symptoms. Arch Gen Psychiatry 37:51–59Google Scholar
  34. Sheehan DV (1982) Panic attacks and phobias. N Engl J Med 307:156–158Google Scholar
  35. Sheehan DV, Coleman JH, Greenblatt DJ (1984) Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 4:66–75Google Scholar
  36. Sheehan DV (1986) The tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics 27 (11):10–16Google Scholar
  37. Shehi M, Patterson WM (1984) Treatment of panic attacks with alprazolam and propranolol. Am J Psychiatry 141:900–901Google Scholar
  38. Sherman AD, Sacquitne JL, Petty F (1982) Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 16:449–454Google Scholar
  39. Spier SA, Rosenbaum JF, Woods SW (1986) Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 47:238–243Google Scholar
  40. Steele RGD, Torrie JH (1985) Principles and Procedures of statistics. McGraw-Hill, New YorkGoogle Scholar
  41. Tyrer P, Candy J, Kelly D (1973) Phenelzine in phobic anxiety: a controlled trial. Psychol Med 3:121–124Google Scholar
  42. Vogel RA, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology 21:1–7Google Scholar
  43. Zitrin CM, Klein DF, Woener MG (1980) Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 37:63–72Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • David J. Fontana
    • 1
  • Timothy J. Carbary
    • 1
  • Randall L. Commissaris
    • 1
    • 2
  1. 1.Department of Pharmaceutical Sciences, College of Pharmacy and AHPWayne State UniversityDetroitUSA
  2. 2.Department of Psychiatry, School of MedicineWayne State UniversityDetroitUSA

Personalised recommendations